Bengaluru-based biotechnology startup, CrisprBits Private Limited, has inaugurated a CRISPR gene editing and diagnostics ...

CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

"We’re in very different place," the CEO of Editas says, citing the CRISPR pioneer's plans to get its first treatments into ...

With that in mind, let's consider two stocks that haven't performed well recently and are now near their 52-week lows but that are still worth investing in: CRISPR Therapeutics (NASDAQ: CRSP) and ...

More than three dozen chemistry laureates join broad coalition to advocate for high risk, high reward research to keep the ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Recent TAU study demonstrates how a crucial but underexplored process of DNA transfer between bacteria affects its defense ...

From fighting diseases to determining why you can't stand cilantro, genetics are the silent architects of your life. Here's ...

Vertex Pharmaceuticals (NASDAQ: VRTX) is a biotechnology company with a strong track record of success in developing ...

Colossal Biosciences wants to bring back the woolly mammoth and has raised $200 million at a $10.2 billion valuation to do it ...

Researchers at the Broad Institute of MIT and Harvard have developed a gene-editing treatment for prion disease that extends ...

Not dying” is the worst way to live.  Bryan Johnson has a single goal: Don’t die. The 47-year-old biotech millionaire has spent the past four years of his life as the human subject of Project ...